Journal
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/psp4.13004
Keywords
-
Categories
Ask authors/readers for more resources
This study developed a population pharmacokinetics model for saliva and plasma, and evaluated its predictive performance in estimating the area under the concentration-time curve at steady state (AUC(ss)) based on saliva samples. The results showed that saliva can be used as an alternative matrix to plasma in therapeutic drug monitoring (TDM) of busulfan (BU). Bayesian maximum a posteriori (MAP) optimization was used to predict AUC(ss) from saliva concentration, which can be used for personalized dosing of BU.
Therapeutic drug monitoring (TDM) of busulfan (BU) is currently performed by plasma sampling in patients undergoing hematopoietic stem cell transplantation (HSCT). Saliva samples are considered a noninvasive TDM matrix. Currently, no salivary population pharmacokinetics (PopPKs) model for BU available. This study aimed to develop a PopPK model that can describe the relationship between plasma and saliva kinetics in patients receiving intravenous BU. The performance of the model in predicting the area under the concentration-time curve at steady state (AUC(ss)) based on saliva samples is evaluated. Sixty-six patients with HSCT were recruited and administered 0.8 mg/kg BU intravenously. A PopPK model for saliva and plasma was developed using the nonlinear mixed effects model. Bayesian maximum a posteriori (MAP) optimization was used to estimate the model's predictive performance. Plasma and saliva PKs were adequately described with a one-compartment model and a scaled central compartment. Body surface area correlated positively with both clearance and apparent volume of distribution (Vd), whereas alkaline phosphatase correlated negatively with Vd. Simulations demonstrated that the percentage root mean squared prediction error and lower and upper limits of agreements reduced to 10.02% and -16.96% to 22.86% based on five saliva samples. Saliva can be used as an alternative matrix to plasma in TDM of BU. The AUC(ss) can be predicted from saliva concentration by Bayesian MAP optimization, which can be used to design personalized dosing for BU.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available